APTX - Aptinyx PTSD Trial And Other News: The Good Bad And Ugly Of Biopharma
Aptinyx Reports Completion of Enrolment in NYX-783 Trial
Aptinyx (APTX) reported completion of enrollment in its NYX-783 trial. This phase 2 study aims to assess the safety and efficacy of NYX-783 in treating patients with post-traumatic stress disorder (PTSD). The company expects the data to be out later this year. The results will be used for informing further development for the drug candidate.
The Phase 2 exploratory study is a placebo controlled, multi-center, double blind, Sequential Parallel Comparison Design study. It aims to enroll 160 patients which will then be randomized into three